TORONTO--(BUSINESS WIRE)-- Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP0) (“Predictmedix†or the “Companyâ€), an emerging leader in AI-powered health and safety technology, is pleased to announce that its Chief Operating Officer and Co-founder, Dr. Rahul Kushwah, will be presenting at the prestigious 25th MK Investment Conference in Munich, Germany, on October 1, 2025.
The MK Investment Conference, hosted by Michael Kott and CM-Equity AG, is one of Europe’s most anticipated investment gatherings. A large and diverse investor audience is expected to attend, with strong interest in AI, Longevity, Tech, and ESG sectors. The event serves as a gateway to exclusive investment opportunities, including innovative private companies and upcoming IPOs.
“AI is the major tech theme today. AI touches all lives, and our technology is built with that self-evident intent,†said Dr. Rahul Kushwah, COO of Predictmedix AI. “At Predictmedix, we are positioned in the sweet spot of the AI revolution—delivering real-world solutions with meaningful impact in healthcare and beyond.â€
Predictmedix AI’s presentation will highlight its proprietary AI-powered technologies, designed to redefine health management, clinical trials and screening with greater accessibility, efficiency, and scale. With investor appetite for AI at an all-time high, the Company looks forward to sharing its growth vision, milestones, and investment potential with global capital market leaders in Munich.
Details of the company’s recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at:
About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA:3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company’s Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI’s proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on , or .
Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Actâ€), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Personsâ€, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
